Contact Allergy to Topical Corticosteroids in Atopic Dermatitis: Diagnostic Gaps in Baseline Patch Testing

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Anna Zaryczańska, Małgorzata Sokołowska‐Wojdyło, Aleksandra Wilkowska, Elżbieta Grubska‐Suchanek, Roman J. Nowicki, Magdalena Trzeciak
Natura: Artículo Open Access
Pubblicazione: Wiley 2026
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867004983353802752
author Anna Zaryczańska
Małgorzata Sokołowska‐Wojdyło
Aleksandra Wilkowska
Elżbieta Grubska‐Suchanek
Roman J. Nowicki
Magdalena Trzeciak
author_facet Anna Zaryczańska
Małgorzata Sokołowska‐Wojdyło
Aleksandra Wilkowska
Elżbieta Grubska‐Suchanek
Roman J. Nowicki
Magdalena Trzeciak
Anna Zaryczańska
Małgorzata Sokołowska‐Wojdyło
Aleksandra Wilkowska
Elżbieta Grubska‐Suchanek
Roman J. Nowicki
Magdalena Trzeciak
collection Wiley Open Access
contents Contact Allergy to Topical Corticosteroids in Atopic Dermatitis: Diagnostic Gaps in Baseline Patch Testing Anna Zaryczańska Małgorzata Sokołowska‐Wojdyło Aleksandra Wilkowska Elżbieta Grubska‐Suchanek Roman J. Nowicki Magdalena Trzeciak Contact Dermatitis ABSTRACT Background Chronic exposure to topical corticosteroids (TCS) in patients with atopic dermatitis (AD) may increase the risk of allergic contact dermatitis (ACD), which can mimic flares of the underlying disease and remain underrecognized. Objectives To evaluate patterns of TCS sensitization in patients with AD compared with patients without AD, with particular emphasis on the diagnostic limitations of baseline patch testing and the effect of test vehicle on allergen detection. Methods In this prospective study conducted between September 2023 and January 2024, 80 patients with AD and 80 patients without AD underwent patch testing. The corticosteroid markers included in the Polish Baseline Series were budesonide 0.01% pet. and tixocortol pivalate 0.1% pet. The extended corticosteroid panel additionally included clobetasol‐17‐propionate 1.0% pet. and hydrocortisone‐17‐butyrate 1.0%, tested in petrolatum (pet.) and ethanol (alc.). Patch test readings were performed at 48, 72 h, and Day 7. Results Sensitization to hydrocortisone‐17‐butyrate was significantly more frequent in patients with AD than in patients without AD (23.8% vs. 8.8%; p  = 0.018; OR 3.25, 95% CI 1.28–8.25). Positive reactions occurred exclusively to hydrocortisone‐17‐butyrate 1.0% in ethanol, whereas hydrocortisone‐17‐butyrate 1.0% in petrolatum was negative in all tested subjects. No positive reactions were observed to budesonide or tixocortol pivalate. Sensitization to clobetasol‐17‐propionate was uncommon and observed only in adults. Most reactions were first clearly detectable at 72 h or increased in intensity between 48 and 72 h, and one paediatric patient with AD had a delayed positive reaction detectable only on Day 7. Conclusions The Polish Baseline Series alone may fail to detect some potentially clinically relevant TCS sensitizations in selected patients with AD. Extended corticosteroid testing, attention to the test vehicle, and Day 7 readings may improve case detection in selected clinical scenarios, particularly in patients with persistent or apparently treatment‐refractory AD. 10.1111/cod.70192 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1111/cod.70192
format Artículo Open Access
id wiley_oa_10_1111_cod_70192
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle Contact Allergy to Topical Corticosteroids in Atopic Dermatitis: Diagnostic Gaps in Baseline Patch Testing
Anna Zaryczańska
Małgorzata Sokołowska‐Wojdyło
Aleksandra Wilkowska
Elżbieta Grubska‐Suchanek
Roman J. Nowicki
Magdalena Trzeciak
Contact Dermatitis
Contact Allergy to Topical Corticosteroids in Atopic Dermatitis: Diagnostic Gaps in Baseline Patch Testing Anna Zaryczańska Małgorzata Sokołowska‐Wojdyło Aleksandra Wilkowska Elżbieta Grubska‐Suchanek Roman J. Nowicki Magdalena Trzeciak Contact Dermatitis ABSTRACT Background Chronic exposure to topical corticosteroids (TCS) in patients with atopic dermatitis (AD) may increase the risk of allergic contact dermatitis (ACD), which can mimic flares of the underlying disease and remain underrecognized. Objectives To evaluate patterns of TCS sensitization in patients with AD compared with patients without AD, with particular emphasis on the diagnostic limitations of baseline patch testing and the effect of test vehicle on allergen detection. Methods In this prospective study conducted between September 2023 and January 2024, 80 patients with AD and 80 patients without AD underwent patch testing. The corticosteroid markers included in the Polish Baseline Series were budesonide 0.01% pet. and tixocortol pivalate 0.1% pet. The extended corticosteroid panel additionally included clobetasol‐17‐propionate 1.0% pet. and hydrocortisone‐17‐butyrate 1.0%, tested in petrolatum (pet.) and ethanol (alc.). Patch test readings were performed at 48, 72 h, and Day 7. Results Sensitization to hydrocortisone‐17‐butyrate was significantly more frequent in patients with AD than in patients without AD (23.8% vs. 8.8%; p  = 0.018; OR 3.25, 95% CI 1.28–8.25). Positive reactions occurred exclusively to hydrocortisone‐17‐butyrate 1.0% in ethanol, whereas hydrocortisone‐17‐butyrate 1.0% in petrolatum was negative in all tested subjects. No positive reactions were observed to budesonide or tixocortol pivalate. Sensitization to clobetasol‐17‐propionate was uncommon and observed only in adults. Most reactions were first clearly detectable at 72 h or increased in intensity between 48 and 72 h, and one paediatric patient with AD had a delayed positive reaction detectable only on Day 7. Conclusions The Polish Baseline Series alone may fail to detect some potentially clinically relevant TCS sensitizations in selected patients with AD. Extended corticosteroid testing, attention to the test vehicle, and Day 7 readings may improve case detection in selected clinical scenarios, particularly in patients with persistent or apparently treatment‐refractory AD. 10.1111/cod.70192 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Contact Allergy to Topical Corticosteroids in Atopic Dermatitis: Diagnostic Gaps in Baseline Patch Testing
topic Contact Dermatitis
url https://onlinelibrary.wiley.com/doi/10.1111/cod.70192